Free Trial

Sutro Biopharma (STRO) Competitors

Sutro Biopharma logo
$0.76 +0.00 (+0.13%)
As of 07/3/2025 02:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

STRO vs. TRDA, ALLO, TSVT, ADCT, ANNX, AMRN, INZY, SGMT, RNAC, and CRVS

Should you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include Entrada Therapeutics (TRDA), Allogene Therapeutics (ALLO), 2seventy bio (TSVT), ADC Therapeutics (ADCT), Annexon (ANNX), Amarin (AMRN), Inozyme Pharma (INZY), Sagimet Biosciences (SGMT), Cartesian Therapeutics (RNAC), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry.

Sutro Biopharma vs. Its Competitors

Sutro Biopharma (NASDAQ:STRO) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

In the previous week, Entrada Therapeutics had 14 more articles in the media than Sutro Biopharma. MarketBeat recorded 14 mentions for Entrada Therapeutics and 0 mentions for Sutro Biopharma. Entrada Therapeutics' average media sentiment score of 0.13 beat Sutro Biopharma's score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Sutro Biopharma Neutral
Entrada Therapeutics Neutral

Sutro Biopharma has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.11, indicating that its share price is 111% less volatile than the S&P 500.

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 3.6% of Sutro Biopharma shares are owned by company insiders. Comparatively, 8.1% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sutro Biopharma presently has a consensus price target of $6.11, indicating a potential upside of 699.25%. Entrada Therapeutics has a consensus price target of $25.67, indicating a potential upside of 254.76%. Given Sutro Biopharma's higher probable upside, equities research analysts plainly believe Sutro Biopharma is more favorable than Entrada Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sutro Biopharma
1 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25
Entrada Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

Entrada Therapeutics has higher revenue and earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sutro Biopharma$66.43M0.97-$227.46M-$2.98-0.26
Entrada Therapeutics$210.78M1.30$65.63M$0.818.93

Entrada Therapeutics has a net margin of 14.39% compared to Sutro Biopharma's net margin of -373.66%. Entrada Therapeutics' return on equity of 5.84% beat Sutro Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Sutro Biopharma-373.66% -347.60% -59.46%
Entrada Therapeutics 14.39%5.84%4.61%

Summary

Entrada Therapeutics beats Sutro Biopharma on 13 of the 16 factors compared between the two stocks.

Get Sutro Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STRO vs. The Competition

MetricSutro BiopharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$64.46M$2.91B$5.55B$9.04B
Dividend YieldN/A2.44%5.22%3.99%
P/E Ratio-0.2621.5627.6620.24
Price / Sales0.97280.51419.21118.06
Price / CashN/A42.7336.8958.10
Price / Book1.427.518.035.67
Net Income-$227.46M-$55.14M$3.18B$249.21M
7 Day Performance4.22%4.61%2.93%3.28%
1 Month Performance-9.79%0.90%1.72%3.95%
1 Year Performance-73.80%5.40%34.39%20.98%

Sutro Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STRO
Sutro Biopharma
3.1994 of 5 stars
$0.77
+0.1%
$6.11
+699.3%
-73.8%$64.46M$66.43M-0.26240
TRDA
Entrada Therapeutics
3.5167 of 5 stars
$7.04
-1.1%
$25.67
+264.6%
-48.8%$267.17M$210.78M8.69110Insider Trade
ALLO
Allogene Therapeutics
3.0124 of 5 stars
$1.22
-0.8%
$8.44
+592.2%
-43.9%$266.85M$20K-0.99310
TSVT
2seventy bio
N/A$5.00
flat
$5.00
N/A$266.15M$48.37M-2.69440
ADCT
ADC Therapeutics
1.5475 of 5 stars
$2.68
-3.2%
$7.75
+189.2%
-13.8%$265.80M$70.84M-1.85310
ANNX
Annexon
2.2971 of 5 stars
$2.38
flat
$12.50
+425.2%
-34.2%$261.12MN/A-2.0260Positive News
AMRN
Amarin
0.7853 of 5 stars
$12.60
+0.5%
$7.00
-44.4%
+9.9%$260.95M$228.61M-3.46360
INZY
Inozyme Pharma
3.42 of 5 stars
$3.99
flat
$11.75
+194.5%
N/A$257.60MN/A-2.3650News Coverage
Analyst Upgrade
SGMT
Sagimet Biosciences
2.3894 of 5 stars
$8.36
-4.1%
$23.17
+177.1%
+175.2%$256.44M$2M-4.758
RNAC
Cartesian Therapeutics
1.4335 of 5 stars
$9.83
+0.7%
$43.00
+337.4%
-34.1%$255.09M$38.91M-0.1964
CRVS
Corvus Pharmaceuticals
2.4724 of 5 stars
$3.73
-5.8%
$15.00
+302.1%
+116.2%$254.27MN/A-3.8130Positive News
Insider Trade

Related Companies and Tools


This page (NASDAQ:STRO) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners